vimarsana.com

Page 24 - Primary Sclerosing Cholangitis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Chemomab to Present at Oppenheimer s Virtual Rare and Orphan Disease Summit

Chemomab to Present at Oppenheimer s Virtual Rare and Orphan Disease Summit USA - English Share this article Share this article TEL AVIV, Israel, May 12, 2021 /PRNewswire/ Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced that the company s CEO, Dr. Adi Mor will present a corporate update at Oppenheimer s virtual Rare and Orphan Disease Summit on May 21 st, 2021. Webcast link may be accessed here. The presentation will be available for 30 days following the event on the Company s investors section at the Chemomab website.

Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in Non-Alcoholic Steatohepatitis (NASH)

Share this article Share this article TEL-AVIV, Israel, April 26, 2021 /PRNewswire/  Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced enrollment of the first patient in its Phase 2a study of CM-101 in Non-Alcoholic Steatohepatitis (NASH). CM-101 is a first-in-class humanized monoclonal antibody designed to bind to and block CCL24 activity, an important chemokine activity that stimulates inflammation and the development of fibrosis. The Phase 2a study is a multi-center, randomized, double-blind, placebo-controlled, multiple dose study designed to assess the mechanism of action, safety, pharmacokinetics and pharmacodynamic effects, as well as the anti-fibrotic effects of subcutaneous CM-101 in NASH patients with fibrosis stage F2-F3. The trial will enroll 40 patients and is anticipated to complete enrollment by the end

Burnham widow launches special lighthouse artwork in husband s memory

A Burnham-On-Sea widow has teamed up with a local artist to launch a unique image of Burnham’s lighthouse in her husband’s memory and to raise funds for two very special causes. As reported a year ago here, Amy Bridgewater’s husband, Andrew Bridgewater sadly passed away at the age of 36 after suffering heart failure. Now, Amy and a local artist have launched digital Lino prints of Burnham’s iconic beach lighthouse, pictured here. The landmark had a special meaning to the couple. She says: “In memory of Andrew and with a wish to help those who have likely suffered even more as a result of the pandemic, in the absence of being able to meet and raise money in person, I wanted to recognise and say thank you to the people who had supported and helped Andrew through his illnesses.”

Chemomab Completes Merger with Anchiano Therapeutics

Chemomab Completes Merger with Anchiano Therapeutics USA - English Combined company will focus on advancing Chemomab s CM-101 currently in Phase 2 for rare fibrotic indications Company to receive gross proceeds of $45.5 Million from a PIPE financing, led by healthcare-focused investors Cormorant Asset Management, OrbiMed, Peter Thiel and Christian Angermayer s Presight Capital and Apeiron Investment Group News provided by Share this article Share this article TEL-AVIV, Israel, March. 16, 2021 /PRNewswire/ Chemomab Ltd., a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced the completion of its merger with Anchiano Therapeutics Ltd. ( Anchiano ).

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.